Metastatic breast cancer – Highlights
In this concise summary, we highlight three of the key ESMO 2023 abstracts related to metastatic breast cancer, with a specific focus on antibody-drug conjugates.
In this concise summary, we highlight three of the key ESMO 2023 abstracts related to metastatic breast cancer, with a specific focus on antibody-drug conjugates.
Neoadjuvant chemotherapy (NACT) has become a mainstay of treatment for patients with triple-negative breast cancer (TNBC), and human epidermal growth factor 2 (HER2) positive BC. In these patients pathological complete response (pCR) is correlated with long term outcome and allows to adapt adjuvant treatment. Some patients with hormone receptor (HR) positive HER2-negative BC also require NACT, mainly because of locoregionally advanced disease or aggressive biology.
KRAS, part of the Ras superfamily, is an oncogene that is mutated in a significant portion of cancer cases. The protein functions as a GTPase, acting as a molecular switch that regulates cell proliferation, growth, and survival. Mutations in KRAS are associated with poor prognosis. Targeting the KRAS protein has been a substantial hurdle for many years. The clinical landscape of KRAS-targeted therapies has recently seen promising developments (1). Swissmedic’s approval of sotorasib, a drug specifically targeting the KRASG12C mutation, marks a significant milestone, as this has become a new 2nd-line treatment option in KRASG12C mutated metastatic non-small cell lung cancer (NSCLC). Here, we summarize a phase 1 study, presented at the ESMO annual meeting 2023, of a promising new panRAS inhibitor.
Upper GI Keynote-811 Since 2009, trastuzumab combined with chemotherapy has been the standard of care for HER2-positive metastatic gastric cancer (mG) and gastroesophageal junction cancer (GEJ), based on the results of the phase 3 ToGA trial (1). In recent years, integrating tumor-specific antibodies with PD-1 inhibitors, has demonstrated enhanced immune infiltration and T-cell response in preclinical studies, effectively countering tolerogenic dendritic cells (2).
This phase 3 trial enrolled 432 patients with previously untreated CLL and coexisting medical conditions. The patients were randomized 1:1 to receive either venetoclax plus obinutuzumab or chlorambucil combined with the same obinutuzumab regimen.
Final analysis of the MASTER trial: MRD-driven Daratumumab-KRd therapy in newly diagnosed MM patients Dr. Costa presented the final analysis of the phase 2 MASTER trial (1)
In dieser Ausgabe berichten wir von aktuellen Studienergebnissen, die an verschiedenen europäischen und amerikanischen Kongressen präsentiert und diskutiert wurden. Gerne möchte ich Ihnen hier eine aktuelle Studie vorstellen, die sich mit der Forschung im Bereich der Onkologie insgesamt befasst; eine Studie, die das Europäische Patentamt (EPA) a nlässlich des Weltkrebstages veröffentlicht hat (1).
Preoperative Stereotactic Radiosurgery for Brain Metastases: A Paradigm Shift? Postoperative stereotactic radiosurgery (SRS), predominantly in the form of single fraction (SF) SRS, has been established as the standard care following the resection of brain metastases, providing significant benefits in cavity local control (1).
Ältere Patienten mit einem fortgeschrittenen Hodgkin Lymphom können von einer Therapie mit Nivolumab-AVD im Vergleich zu Bv-AVD profitieren.
Heutige Optionen in der Reproduktionstherapie
Trotz der zunehmenden Verbesserung der Lebenserwartung bleiben Krebserkrankungen weiterhin ein Langzeitproblem, das auch junge Erwachsene und Kinder betrifft. Die Anzahl an Patientinnen und Patienten, die ihre Familienplanung zum Zeitpunkt der Diagnose noch nicht abgeschlossen haben, ist in den letzten Jahren gestiegen und damit die Nachfrage nach einer Fertilitätsberatung und der Anlage einer Fertilitätsreserve. Der Beitrag bezieht sich auf Frauen und Männer mit Krebserkrankung im reproduktiven Alter.